secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009810
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna plans BLA for miv-cel in SPS in 1H 2026; Christi Shaw appointed Executive Chair
--------------------------------------------------------------------------------

- BLA submission for miv-cel in stiff person syndrome expected in 1H 2026 following positive registrational data.
- Cash, cash equivalents, and marketable securities approx. $279M as of Dec 31, 2025; follow-on offering raised ~$105M.
- First patient enrolled in Phase 3 registrational trial of miv-cel in generalized myasthenia gravis.
- Christi Shaw (former Kite CEO) appointed Executive Chairperson; Ian Clark remains on board.
- Company plans to achieve SPS launch readiness by year-end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526009810/0001193125-26-009810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526009810/kytx-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer